Detalhe da pesquisa
1.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol
; 70(5): 1008-1015, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982526
2.
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
J Viral Hepat
; 26(1): 118-125, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187599
3.
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
J Hepatol
; 62(1): 41-7, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25152207
4.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Gastroenterology
; 146(3): 744-753.e3, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24316262
5.
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med
; 364(25): 2405-16, 2011 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21696307
6.
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Liver Int
; 34(7): e217-28, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24251988
7.
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Hepatology
; 56(6): 2039-50, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22706730
8.
Current management of delta hepatitis.
Liver Int
; 33 Suppl 1: 195-7, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23286865
9.
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
Ther Drug Monit
; 34(2): 165-70, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22406654
10.
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.
Ther Drug Monit
; 34(6): 722-8, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23149444
11.
Pegylated interferon therapy of chronic hepatitis D: in need of revision.
Hepatology
; 61(4): 1109-11, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25348580
12.
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
Antivir Ther
; 14(2): 143-54, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19430089
13.
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Am J Gastroenterol
; 103(10): 2481-7, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18702647
14.
Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Ann N Y Acad Sci
; 1112: 368-74, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17600286
15.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Ann Intern Med
; 140(5): 346-55, 2004 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-14996676
16.
IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
World J Gastroenterol
; 20(36): 13146-52, 2014 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25278709
17.
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
World J Gastroenterol
; 20(44): 16726-33, 2014 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25469044
18.
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Eur J Gastroenterol Hepatol
; 26(1): 52-8, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23719564
19.
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.
Dig Liver Dis
; 46(9): 826-32, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24986781
20.
Response-guided therapy: optimizing treatment now and in the future.
Antivir Ther
; 13 Suppl 1: 1-2, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18432156